Interaction between Posaconazole and Amphotericin B in Concomitant Treatment against Candida albicans In Vivo
Open Access
- 1 February 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (2) , 638-642
- https://doi.org/10.1128/aac.49.2.638-642.2005
Abstract
The interaction of posaconazole and amphotericin B was evaluated in concomitant treatment of Candida albicans systemic infections in immunocompetent mice by using four strains of C. albicans with different susceptibilities to fluconazole. Posaconazole and amphotericin B were each tested at four dose levels alone and in all possible combinations against each C. albicans strain. Survival curves of mice treated with combinations of posaconazole and amphotericin B were statistically compared with those of mice treated with the component monotherapies. Of the 64 total combinations evaluated against the C. albicans strains (16 combinations per strain), 20.3% were more effective in prolonging mouse survival than both of the monotherapies, 45.3% were more effective than one of the monotherapies, and 32.8% were similar to both monotherapies. No evidence of antagonism was observed between posaconazole and amphotericin B in this mouse model, consistent with in vitro results against the same strains.Keywords
This publication has 21 references indexed in Scilit:
- Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated CandidiasisAntimicrobial Agents and Chemotherapy, 2004
- Combination and Sequential Antifungal Therapy for Invasive Aspergillosis: Review of Published In Vitro and In Vivo Interactions and 6281 Clinical Cases from 1966 to 2001Clinical Infectious Diseases, 2003
- Itraconazole Preexposure Attenuates the Efficacy of Subsequent Amphotericin B Therapy in a Murine Model of Acute Invasive Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2001
- Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida albicans In Vitro and in a Rabbit Model of Endocarditis and PyelonephritisAntimicrobial Agents and Chemotherapy, 2001
- Interactions between Triazoles and Amphotericin B against Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2000
- In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and CandidaAntimicrobial Agents and Chemotherapy, 2000
- Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus MonkeysAntimicrobial Agents and Chemotherapy, 2000
- Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosine Monotherapies in Treatment of Experimental Endocarditis, Endophthalmitis, and Pyelonephritis Due to Candida albicansAntimicrobial Agents and Chemotherapy, 1999
- Combination therapy of murine invasive candidiasis with fluconazole and amphotericin BAntimicrobial Agents and Chemotherapy, 1995